Oryzon Genomics (STU:ORN) Total Stockholders Equity : €82.35 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Oryzon Genomics Total Stockholders Equity?

Oryzon Genomics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €82.35 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Oryzon Genomics's Book Value per Share for the quarter that ended in Mar. 2024 was €1.31. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Oryzon Genomics's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.00.

Oryzon Genomics Total Stockholders Equity Historical Data

The historical data trend for Oryzon Genomics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oryzon Genomics Total Stockholders Equity Chart

Oryzon Genomics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

61.63

76.77

71.41

73.47

82.89

Oryzon Genomics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial															71.83	78.78	78.57	82.89	82.35

Oryzon Genomics (STU:ORN) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Oryzon Genomics's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(82.348	-	0)	/	62.7322
	=	1.31

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Oryzon Genomics's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	82.348
	=	0.00

Oryzon Genomics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Oryzon Genomics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Oryzon Genomics (STU:ORN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oryzon Genomics SA (STU:ORN) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

ORYZF:USA ORY:Spain

Address

Sant Ferran 74, Cornellà de Llobregat, Barcelona, ESP, 08940

Website

http://www.oryzon.com

Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.